INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Rodman & Renshaw

Research analysts at Rodman & Renshaw started coverage on shares of INmune Bio (NASDAQ:INMB) in a research report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $23.00 price target on the stock. Rodman & Renshaw’s target price indicates a potential upside of 190.77% from the company’s previous close.

Separately, Alliance Global Partners began coverage on INmune Bio in a research report on Monday, October 21st. They issued a “buy” rating and a $20.00 price target for the company.

INmune Bio Price Performance

INMB opened at $7.91 on Tuesday. The company has a market capitalization of $175.36 million, a PE ratio of -3.63 and a beta of 1.78. The business has a 50-day moving average of $5.32 and a 200-day moving average of $6.05. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same period in the prior year, the business posted ($0.48) EPS. On average, equities research analysts expect that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of INMB. Financial Advocates Investment Management boosted its holdings in INmune Bio by 17.4% during the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after acquiring an additional 2,000 shares during the period. Rhumbline Advisers acquired a new position in shares of INmune Bio during the 2nd quarter worth about $121,000. Jane Street Group LLC bought a new stake in INmune Bio during the 3rd quarter valued at approximately $79,000. Sanctuary Advisors LLC acquired a new stake in INmune Bio in the 3rd quarter valued at approximately $113,000. Finally, Barclays PLC increased its position in INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after buying an additional 24,906 shares during the period. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.